FDA Grants Approval for Sodium Acetate ANDA220274 by Extrovis
The FDA has granted approval for ANDA220274, a sodium acetate product submitted by Extrovis.
Asset / Drug
Drug and asset intelligence for Extrovis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.